Investigating the role of specific proteins in lung cancer progression
Official title: Rac guanine nucleotide exchange factors in lung cancer
Funded at University of Miami School of Medicine · NIH-11147003 · Data updated 2026-11-12
This study is looking at how certain proteins might help lung cancer grow and spread, especially in patients with a specific gene mutation, to find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | July 31, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $459,139 |
| NIH project number | 7R01CA265999-03 |
| Project ID | NIH-11147003 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, particularly those with KRAS mutations.
✕Less likely to help
Patients with lung cancer types that do not involve KRAS mutations may not benefit from this research.
What this research studies
This research focuses on understanding how certain proteins, known as Rac guanine nucleotide exchange factors (Rac-GEFs), contribute to the progression of lung adenocarcinoma, a common type of lung cancer. By using advanced techniques like CRISPR, researchers will create specific cell lines to study the effects of these proteins on cancer cell movement and invasion. The goal is to identify which Rac-GEFs are crucial for the aggressive behavior of lung cancer cells, particularly those with mutations in the KRAS gene. This could lead to new insights into potential therapeutic targets for lung cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for lung cancer patients.
How similar studies have gone: Other research has shown success in targeting similar pathways in cancer treatment, indicating potential for this approach.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Kazanietz, Marcelo G. — University of Miami School of Medicine
- Study coordinator: Kazanietz, Marcelo G.
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.